{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:11:06Z","timestamp":1788012666294,"version":"build-2784847793"},"reference-count":94,"publisher":"Japanese Circulation Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2026,6,25]]},"DOI":"10.1253\/circj.cj-25-0969","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T22:09:46Z","timestamp":1773958186000},"page":"908-943","source":"Crossref","is-referenced-by-count":2,"title":["JCS 2026 Guideline on Management of Large Vessel Vasculitis"],"prefix":"10.1253","volume":"90","author":[{"given":"Yoshikazu","family":"Nakaoka","sequence":"first","affiliation":[{"name":"Department of Vascular Physiology, Research Institute, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Kawasaki Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Sugihara","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Nagasaka","sequence":"additional","affiliation":[{"name":"Institute of Science Tokyo"},{"name":"Department of Rheumatology, Ome Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Yoshifuji","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Yajima","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Showa Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumika","family":"Aono","sequence":"additional","affiliation":[{"name":"Takayasu Arteritis Patient Association (akebonokai Association)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Saitama Medical Center, Saitama Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Ishizu","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Iida","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Ageo Central General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatoyo","family":"Kiko","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Maejima","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine and Nephrology, Dokkyo Medical University Nikko Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Miyamae","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology, Tokyo Women&apos;s Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Tokyo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Nanki","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Niiro","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Graduate School of Medical Sciences, Kyushu University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Ota","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Tohoku University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Okochi","sequence":"additional","affiliation":[{"name":"Rheumatic Disease and Vasculitis Support Network Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenei","family":"Sada","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Kochi Medical School, Kochi University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Shigematsu","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, International University of Health and Welfare Mita Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhito A.","family":"Uchida","sequence":"additional","affiliation":[{"name":"Division of Kidney, Diabetes and Endocrine Diseases, Medical Development Field, Okayama University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chizuko","family":"Aoki-Kamiya","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoh","family":"Arita","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Japan Community Healthcare Organization Osaka Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaya","family":"Handa","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kobe City Medical Center General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Hiwa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Shimane University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuhei","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Graduate School of Medicine, Osaka Metropolitan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ishizaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Yokohama City University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Iwahashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Tokyo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunology, Allergy and Immunology Center, Aichi Children\u2019s Health and Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Kadoba","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kamiyama","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Yokohama City University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Kawazoe","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kida","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genki","family":"Kidoguchi","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Division of Clinical Nephrology and Rheumatology, Kidney Research Center, Niigata University Graduate School of Medical and Dental Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Departoment of Diagnostic Pathology, Fujita Health University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kurata","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tokyo Women&apos;s Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshia","family":"Miyawaki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Rheumatology, Endocrinology and Metabolism"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Nakagama","sequence":"additional","affiliation":[{"name":"Department of Virology, Graduate school of Medicine, Osaka Metropolitan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Nishioka","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Kyorin University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuho","family":"Onimaru","sequence":"additional","affiliation":[{"name":"Division of Pathophysiological and Experimental Pathology, Department of Pathology, Graduate School of Medical Sciences, Kyushu University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Onishi","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Therapy for Chronic Kidney Disease, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Public Health and Epidemiology, Meiji Pharmaceutical Univeraity"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Sanada","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Kanazwa University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuuki","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Shirai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tohoku University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Sugano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tokyo Women&apos;s Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Patholofy, Toho University Ohashi Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ya","family":"Tamechika","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Nagoya City University Hospital"},{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuka","family":"Umezawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryu","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Graduate School of Medicine, Osaka Metropolitan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Yanai","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Showa Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuneyasu","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Kao immunity institute, Cedars Sinai Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Amano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, International University of Health and Welfare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuaki","family":"Isobe","sequence":"additional","affiliation":[{"name":"Sakakibara Heart Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kitaoka","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Tanemoto","sequence":"additional","affiliation":[{"name":"Kawasaki University of Medical Welfare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Japanese Circulation Society Joint Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","unstructured":"1. Kussmaul A, Maier R. \u00dcber eine bisher nicht beschriebene eigenth\u00fcmliche Arterienerkrankung (Periarteritis nodosa), die mit Morbus Brightii und rapid fortschreitender, allgemeiner Muskell\u00e4hmung einhergeht. <i>Dtsch Arch Klin Med<\/i> 1866; 1: 484\u2013518."},{"key":"2","unstructured":"2. Hutchinson J. Diseases of the arteries. <i>Arch Surg<\/i> 1890; 1: 323\u2013333."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Horton BT, Magath TB, Brown GE. Arteritis of the temporal vessels. <i>Arch Intern Med<\/i> 1934; 53: 400\u2013409.","DOI":"10.1001\/archinte.1934.00160090077007"},{"key":"4","unstructured":"4. Takayasu M. Peculiar changes of the central retinal vessels. <i>Journal of Japanese Ophthalmological Society<\/i> 1908; 12: 554\u2013555 [in Japanese]."},{"key":"5","unstructured":"5. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. <i>Arerugi<\/i> 1967; 16: 178\u2013222 [in Japanese]."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Buerger L. Thrombo-angiitis obliterans: A study of the vascular lesions leading to presenile spontaneous gangrene. <i>Am J Med Sci<\/i> 1908; 136: 567\u2013580.","DOI":"10.1097\/00000441-190810000-00011"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Davies DJ, Moran JE, Niall JF, Ryan GB. Segmental necrotising glomerulonephritis with antineutrophil antibody: Possible arbovirus aetiology? <i>Br Med J (Clin Res Ed)<\/i> 1982; 285: 606.","DOI":"10.1136\/bmj.285.6342.606"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. van der Woude FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, van Es LA, et al. Autoantibodies against neutrophils and monocytes: Tool for diagnosis and marker of disease activity in Wegener\u2019s granulomatosis. <i>Lancet<\/i> 1985; 1: 425\u2013429.","DOI":"10.1016\/S0140-6736(85)91147-X"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: Proposal of an international consensus conference. <i>Arthritis Rheum<\/i> 1994; 37: 187\u2013192.","DOI":"10.1002\/art.1780370206"},{"key":"10","unstructured":"10. Guideline for management of vasculitis syndrome (JCS 2008). <i>Circ J<\/i> 2008; 72(Suppl IV): 1260\u20131275."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. <i>Arthritis Rheum<\/i> 2013; 65: 1\u201311.","DOI":"10.1002\/art.37715"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Isobe M, Amano K, Arimura Y, Ishizu A, Ito S, Kaname S, et al. JCS 2017 guideline on management of vasculitis syndrome: Digest version. <i>Circ J<\/i> 2020; 84: 299\u2013359.","DOI":"10.1253\/circj.CJ-19-0773"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sada KE, Nagasaka K, Kaname S, Nango E, Kishibe K, Dobashi H, et al. Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of microscopic polyangiitis and granulomatosis with polyangiitis: The 2023 update \u2013 secondary publication. <i>Mod Rheumatol<\/i> 2024; 34: 559\u2013567.","DOI":"10.1093\/mr\/road081"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: Results from a randomized, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). <i>Ann Rheum Dis<\/i> 2018; 77: 348\u2013354.","DOI":"10.1136\/annrheumdis-2017-211878"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. <i>N Engl J Med<\/i> 2017; 377: 317\u2013328.","DOI":"10.1056\/NEJMoa1613849"},{"key":"16","unstructured":"16. Harigai M, editor. 2020 guidance for the treatment of antiphospholipid syndrome, eosinophilic granulomatosis with polyangiitis, polyarteritis nodosa, and rheumatoid vasculitis. Shindan-to-Chiryo-shya, 2021 [in Japanese]."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Abe Y, Fujii T, Miyawaki Y, Sugihara T, Uchida HA, Maejima Y, et al. Real-world clinical decisions of physicians in the management of Takayasu arteritis and giant cell arteritis in Japan: A cross-sectional web questionnaire survey. <i>Mod Rheumatol<\/i> 2024; 34: 1194\u20131201.","DOI":"10.1093\/mr\/roae034"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Miyawaki Y, Fujii T, Anan K, Kodera M, Kikuchi M, Sada KE, et al. Concordance between practice and published evidence in the management of ANCA-associated vasculitis in Japan: A cross-sectional web-questionnaire survey. <i>Mod Rheumatol<\/i> 2023; 33: 990\u2013997.","DOI":"10.1093\/mr\/roac118"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Arita Y, Asano R, Ueda J, Seike Y, Inoue Y, Ogo T, et al. Perioperative management of Takayasu arteritis for cardiac surgery: Review and single-center experience. <i>Circ J<\/i> 2025; 89: 1849\u20131856.","DOI":"10.1253\/circj.CJ-24-0496"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Sugihara T, Nakaoka Y, Uchida HA, Yoshifuji H, Maejima Y, Watanabe Y, et al. Establishing clinical remission criteria and the framework of a treat-to-target algorithm for Takayasu arteritis: Results of a Delphi exercise carried out by an expert panel of the Japan Research Committee of the Ministry of Health, Labour and Welfare for intractable vasculitis. <i>Mod Rheumatol<\/i> 2022; 32: 930\u2013937.","DOI":"10.1093\/mr\/roab081"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Yoshifuji H, Nakaoka Y, Uchida HA, Sugihara T, Watanabe Y, Funakoshi S, et al. Organ damage and quality of life in Takayasu arteritis: Evidence from a national registry analysis. <i>Circ J<\/i> 2024; 88: 285\u2013294.","DOI":"10.1253\/circj.CJ-23-0656"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Ishikawa K, Maetani S. Long-term outcome for 120 Japanese patients with Takayasu\u2019s disease: Clinical and statistical analyses of related prognostic factors. <i>Circulation<\/i> 1994; 90: 1855\u20131860.","DOI":"10.1161\/01.CIR.90.4.1855"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Mutoh T, Shirai T, Fujii H, Ishii T, Harigae H. Insufficient use of corticosteroids without immunosuppressants results in higher relapse rates in Takayasu arteritis. <i>J Rheumatol<\/i> 2020; 47: 255\u2013263.","DOI":"10.3899\/jrheum.181219"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Uchida HA, Nakaoka Y, Sugihara T, Yoshifuji H, Maejima Y, Watanabe Y, et al. Clinical characteristics and treatment outcomes of patients with newly diagnosed Takayasu arteritis in Japan during the first 2 years of treatment: A nationwide retrospective cohort study. <i>Circ J<\/i> 2025; 89: 612\u2013619.","DOI":"10.1253\/circj.CJ-24-0178"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Wang J, Kong X, Ma L, Ding Z, Chen H, Chen R, et al. Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis: An open-label study. <i>Rheumatology (Oxford)<\/i> 2024; 63: 1359\u20131367.","DOI":"10.1093\/rheumatology\/kead387"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Mekinian A, Biard L, Lorenzo D, Novikov PI, Salvarani C, Espitia O, et al. Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: Multicentre retrospective study. <i>RMD Open<\/i> 2023; 9: e002830.","DOI":"10.1136\/rmdopen-2022-002830corr1"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Misra DP, Singh K, Rathore U, Patro P, Tomelleri A, Campochiaro C, et al. The effectiveness of tocilizumab and its comparison with tumor necrosis factor alpha inhibitors for Takayasu arteritis: A systematic review and meta-analysis. <i>Autoimmun Rev<\/i> 2023; 22: 103275.","DOI":"10.1016\/j.autrev.2023.103275"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. <i>Ann Rheum Dis<\/i> 2020; 79: 19\u201330.","DOI":"10.1136\/annrheumdis-2019-215672"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. <i>Arthritis Rheumatol<\/i> 2021; 73: 1349\u20131365.","DOI":"10.1002\/art.41774"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Nakaoka Y, Isobe M, Tanaka Y, Ishii T, Ooka S, Niiro H, et al. Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: Final results of the randomized controlled phase 3 TAKT study. <i>Rheumatology (Oxford)<\/i> 2020; 59: 2427\u20132434.","DOI":"10.1093\/rheumatology\/kez630"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Ohigashi H, Haraguchi G, Konishi M, Tezuka D, Kamiishi T, Ishihara T, et al. Improved prognosis of Takayasu arteritis over the past decade: Comprehensive analysis of 106 patients. <i>Circ J<\/i> 2012; 76: 1004\u20131011.","DOI":"10.1253\/circj.CJ-11-1108"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Padiyar S, Danda D, Goel R, Joseph E, Nair AM, Joseph G, et al. Clinical and angiographic outcomes of mycophenolate versus methotrexate in South Asian patients of Takayasu arteritis: Results from an open-label, outcome-assessor blinded randomized controlled trial. <i>Mod Rheumatol<\/i> 2023; 34: 175\u2013181.","DOI":"10.1093\/mr\/roac157"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. <i>Arthritis Rheum<\/i> 2007; 56: 1000\u20131009.","DOI":"10.1002\/art.22404"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, et al. A randomized, double-blind trial of abatacept (CTLA-4 Ig) for the treatment of Takayasu\u2019s arteritis. <i>Arthritis Rheumatol<\/i> 2017; 69: 846\u2013853.","DOI":"10.1002\/art.40037"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Sugihara T, Yoshifuji H, Uchida HA, Maejima Y, Watanabe Y, Tanemoto K, et al. Establishing clinical remission criteria for giant cell arteritis: Results of a Delphi exercise carried out by an expert panel of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis. <i>Mod Rheumatol<\/i> 2024; 34: 568\u2013575.","DOI":"10.1093\/mr\/road046"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Sugihara T, Hasegawa H, Uchida HA, Yoshifuji H, Watanabe Y, Amiya E, et al. Associated factors of poor treatment outcomes in patients with giant cell arteritis: Clinical implication of large vessel lesions. <i>Arthritis Res Ther<\/i> 2020; 22: 72.","DOI":"10.21203\/rs.2.22145\/v1"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: A phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet<\/i> 2016; 387: 1921\u20131927.","DOI":"10.1016\/S0140-6736(16)00560-2"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Harigai M, Miyamae T, Hashimoto H, Umetsu K, Yamashita K, Nakaoka Y. A multicentre, large-scale, observational study of tocilizumab in patients with giant cell arteritis in Japan. <i>Mod Rheumatol<\/i> 2024; 34: 775\u2013783.","DOI":"10.1093\/mr\/road074"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Kermani TA, Warrington KJ, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, et al. Disease relapses among patients with giant cell arteritis: A prospective, longitudinal cohort study. <i>J Rheumatol<\/i> 2015; 42: 1213\u20131217.","DOI":"10.3899\/jrheum.141347"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Alba MA, Garc\u00eda-Mart\u00ednez A, Prieto-Gonz\u00e1lez S, Tavera-Bahillo I, Corbera-Bellalta M, Planas-Rigol E, et al. Relapses in patients with giant cell arteritis: Prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. <i>Medicine (Baltimore)<\/i> 2014; 93: 194\u2013201.","DOI":"10.1097\/MD.0000000000000033"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: A randomized trial. <i>Ann Intern Med<\/i> 2007; 146: 621\u2013630.","DOI":"10.7326\/0003-4819-146-9-200705010-00004"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Mart\u00ednez-Taboada VM, Rodr\u00edguez-Valverde V, Carre\u00f1o L, L\u00f3pez-Longo J, Figueroa M, Belzunegui J, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. <i>Ann Rheum Dis<\/i> 2008; 67: 625\u2013630.","DOI":"10.1136\/ard.2007.082115"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Seror R, Baron G, Hachulla E, Debandt M, Larroche C, Pu\u00e9chal X, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: Results of a multicentre randomised controlled trial. <i>Ann Rheum Dis<\/i> 2014; 73: 2074\u20132081.","DOI":"10.1136\/annrheumdis-2013-203586"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Dumont A, Parienti JJ, Delmas C, Boutemy J, Maign\u00e9 G, Silva NM, et al. Factors associated with relapse and dependence on glucocorticoids in giant cell arteritis. <i>J Rheumatol<\/i> 2020; 47: 108\u2013116.","DOI":"10.3899\/jrheum.181127"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Samec MJ, Rakholiya J, Langenfeld H, Crowson CS, Abril A, Wang B, et al. Relapse risk and safety of long-term tocilizumab use among patients with giant cell arteritis: A single-enterprise cohort study. <i>J Rheumatol<\/i> 2023; 50: 1310\u20131317.","DOI":"10.3899\/jrheum.2022-1214"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. <i>Arthritis Rheumatol<\/i> 2017; 69: 837\u2013845.","DOI":"10.1002\/art.40044"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Mainbourg S, Addario A, Samson M, Pu\u00e9chal X, Fran\u00e7ois M, Durupt S, et al. Prevalence of giant cell arteritis relapse in patients treated with glucocorticoids: A meta-analysis. <i>Arthritis Care Res<\/i> 2020; 72: 838\u2013844.","DOI":"10.1002\/acr.23901"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. <i>Arthritis Rheum<\/i> 2002; 46: 1309\u20131318.","DOI":"10.1002\/art.10262"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Jover JA, Hern\u00e1ndez-Garc\u00eda C, Morado IC, Vargas E, Ba\u00f1ares A, Fern\u00e1ndez-Guti\u00e9rrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. <i>Ann Intern Med<\/i> 2001; 134: 106\u2013114.","DOI":"10.7326\/0003-4819-134-2-200101160-00010"},{"key":"50","unstructured":"50. Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). <i>Clin Exp Rheumatol<\/i> 2001; 19: 495\u2013501."},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Mahr AD, Jover JA, Spiera RF, Hern\u00e1ndez-Garc\u00eda C, Fern\u00e1ndez-Guti\u00e9rrez B, Lavalley MP, et al. Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data meta-analysis. <i>Arthritis Rheum<\/i> 2007; 56: 2789\u20132797.","DOI":"10.1002\/art.22754"},{"key":"52","unstructured":"52. The Japan College of Rheumatology MTX Clinical Practice Guidelines Subcommittee. Methotrexate (MTX) use and clinical practice guide 2023 [in Japanese]. Yodosha, 2023."},{"key":"53","unstructured":"53. Chevalet P, Barrier JH, Pottier P, Magadur-Joly G, Pottier MA, Hamidou M, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: A one year followup study of 164 patients. <i>J Rheumatol<\/i> 2000; 27: 1484\u20131491."},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: A double-blind, placebo-controlled, randomized prospective clinical trial. <i>Arthritis Rheum<\/i> 2006; 54: 3310\u20133318.","DOI":"10.1002\/art.22163"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Esp\u00edgol-Frigol\u00e9 G, Corbera-Bellalta M, Planas-Rigol E, Lozano E, Segarra M, Garc\u00eda-Mart\u00ednez A, et al. Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis. <i>Ann Rheum Dis<\/i> 2013; 72: 1481\u20131487.","DOI":"10.1136\/annrheumdis-2012-201836"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Samson M, Corbera-Bellalta M, Audia S, Planas-Rigol E, Martin L, Cid MC, et al. Recent advances in our understanding of giant cell arteritis pathogenesis. <i>Autoimmun Rev<\/i> 2017; 16: 833\u2013844.","DOI":"10.1016\/j.autrev.2017.05.014"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Venhoff N, Schmidt WA, Bergner R, Rech J, Unger L, Tony HP, et al. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): A randomized, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Rheumatol<\/i> 2023; 5: e341\u2013e350.","DOI":"10.1016\/S2665-9913(23)00101-7"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Shionoya S. Buerger\u2019s disease: Diagnosis and management. <i>Cardiovasc Surg<\/i> 1993; 1: 207\u2013214.","DOI":"10.1177\/096721099300100302"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Mills JL Sr. Buerger\u2019s disease in the 21st century: Diagnosis, clinical features, and therapy. <i>Semin Vasc Surg<\/i> 2003; 16: 179\u2013189.","DOI":"10.1016\/S0895-7967(03)00023-1"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Olin JW, Shih A. Thromboangiitis obliterans (Buerger\u2019s disease). <i>Curr Opin Rheumatol<\/i> 2006; 18: 18\u201324.","DOI":"10.1097\/01.bor.0000198000.58073.aa"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Papa MZ, Rabi I, Adar R. A point scoring system for the clinical diagnosis of Buerger\u2019s disease. <i>Eur J Vasc Endovasc Surg<\/i> 1996; 11: 335\u2013339.","DOI":"10.1016\/S1078-5884(96)80081-5"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Fazeli B, Poredos P, Kozak M, Pecsvarady Z, Catalano M, Al-Salman MM, et al. Diagnostic criteria for Buerger\u2019s disease: International Consensus of VAS  \u2013  European Independent Foundation in Angiology\/Vascular Medicine. <i>Int Angiol<\/i> 2023; 42: 396\u2013401.","DOI":"10.23736\/S0392-9590.23.05098-8"},{"key":"63","unstructured":"63. Ministry of Health, Labour, and Welfare (MHLW), Japan. Clinical Practice Guideline for ANCA-Related Vasculitis 2023. [in Japanese] MHLW Research Project on Intractable Diseases, 2023."},{"key":"64","unstructured":"64. Shigematsu H, Shigematsu K. Factors affecting the long-term outcome of Buerger\u2019s disease (thromboangiitis obliterans). <i>Int Angiol<\/i> 1999; 18: 58\u201364."},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Watanabe Y, Miyata T, Shigematsu K, Tanemoto K, Nakaoka Y, Harigai M, et al. Current trends in epidemiology and clinical features of thromboangiitis obliterans in Japan: A nationwide survey using the medical support system database. <i>Circ J<\/i> 2020; 84: 1786\u20131796.","DOI":"10.1253\/circj.CJ-19-1165"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Sekhar S, Thomas D, Meera N, Koneri R, Balakrishna P. Progress and incidence of Buerger\u2019s Disease in Bangalore. <i>Internet J Epidemiol<\/i> 2007, https:\/\/ispub.com\/IJE\/6\/1\/8933.","DOI":"10.5580\/1713"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Zheng JF, Chen YM, Chen DY, Lin CH, Chen HH. The incidence and prevalence of thromboangiitis obliterans in Taiwan: A nationwide, population-based analysis of data collected from 2002 to 2011. <i>Clinics (Sao Paulo)<\/i> 2016; 71: 399\u2013403.","DOI":"10.6061\/clinics\/2016(07)08"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Lawrence PF, Lund OI, Jimenez JC, Muttalib R. Substitution of smokeless tobacco for cigarettes in Buerger\u2019s disease does not prevent limb loss. <i>J Vasc Surg<\/i> 2008; 48: 210\u2013212.","DOI":"10.1016\/j.jvs.2008.02.007"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. O\u2019Dell JR, Linder J, Markin RS, Moore GF. Thromboangiitis obliterans (Buerger\u2019s disease) and smokeless tobacco. <i>Arthritis Rheum<\/i> 1987; 30: 1054\u20131056.","DOI":"10.1002\/art.1780300913"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Le Joncour A, Soudet S, Dupont A, Espitia O, Koskas F, Cluzel P, et al. Long-term outcome and prognostic factors of complications in thromboangiitis obliterans (Buerger\u2019s disease): A multicenter study of 224 patients. <i>J Am Heart Assoc<\/i> 2018; 7: e010677.","DOI":"10.1161\/JAHA.118.010677"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Gundogmus CA, Samadli V, Sorkun M, Oguzkurt L. The effect of smoking cessation on the technical success of endovascular treatment for thromboangiitis obliterans. <i>J Vasc Interv Radiol<\/i> 2023; 34: 1038\u20131044.","DOI":"10.1016\/j.jvir.2023.02.008"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Sasajima T, Kubo Y, Inaba M, Goh K, Azuma N. Role of infrainguinal bypass in Buerger\u2019s disease: An eighteen-year experience. <i>Eur J Vasc Endovasc Surg<\/i> 1997; 13: 186\u2013192.","DOI":"10.1016\/S1078-5884(97)80017-2"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Neufang A, Vargas-Gomez C, Ewald P, Vitolianos N, Coskun T, Abu-Salim N, et al. Very distal vein bypass in patients with thromboangiitis obliterans. <i>Vasa<\/i> 2017; 46: 304\u2013309.","DOI":"10.1024\/0301-1526\/a000624"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Arkkila PE. Thromboangiitis obliterans (Buerger\u2019s disease). <i>Orphanet J Rare Dis<\/i> 2006; 1: 14.","DOI":"10.1186\/1750-1172-1-14"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. Piazza G, Creager MA. Thromboangiitis obliterans. <i>Circulation<\/i> 2010; 121: 1858\u20131861.","DOI":"10.1161\/CIRCULATIONAHA.110.942383"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Komiya D, Iwai K, Ohno T. Efficacy of supervised exercise therapy for intermittent claudication in a case with Buerger\u2019s disease. <i>Cureus<\/i> 2023; 15: e43537.","DOI":"10.7759\/cureus.43537"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. Cacione DG, Macedo CR, do Carmo Novaes F, Baptista-Silva JC. Pharmacological treatment for Buerger\u2019s disease. <i>Cochrane Database Syst Rev<\/i> 2020; 5: CD011033.","DOI":"10.1002\/14651858.CD011033.pub4"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Klein-Weigel P, Volz TS, Zange L, Richter J. Buerger\u2019s disease: Providing integrated care. <i>J Multidiscip Healthc<\/i> 2016; 9: 511\u2013518.","DOI":"10.2147\/JMDH.S109985"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. Fujioka A, Yanishi K, Yukawa A, Imai K, Yokota I, Fujikawa K, et al. A multicenter prospective interventional trial of therapeutic angiogenesis using bone marrow-derived mononuclear cell implantation for patients with critical limb-threatening ischemia caused by thromboangiitis obliterans. <i>Circ J<\/i> 2023; 87: 1229\u20131237.","DOI":"10.1253\/circj.CJ-23-0046"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Kondo K, Yanishi K, Hayashida R, Shintani S, Shibata R, Murotani K, et al. Long-term clinical outcomes survey of bone marrow-derived cell therapy in critical limb ischemia in Japan. <i>Circ J<\/i> 2018; 82: 1168\u20131178.","DOI":"10.1253\/circj.CJ-17-0510"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Shimizu Y, Kondo K, Hayashida R, Sasaki K, Ohtsuka M, Fukumoto Y, et al. Therapeutic angiogenesis for patients with no-option critical limb ischemia by adipose-derived regenerative cells: TACT-ADRC multicenter trial. <i>Angiogenesis<\/i> 2022; 25: 535\u2013546.","DOI":"10.1007\/s10456-022-09844-7"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Igari K, Inoue Y, Iwai T. The epidemiologic and clinical findings of patients with Buerger disease. <i>Ann Vasc Surg<\/i> 2016; 30: 263\u2013269.","DOI":"10.1016\/j.avsg.2015.07.014"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83. Ohta T, Ishioashi H, Hosaka M, Sugimoto I. Clinical and social consequences of Buerger disease. <i>J Vasc Surg<\/i> 2004; 39: 176\u2013180.","DOI":"10.1016\/j.jvs.2003.08.006"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84. Kodama A, Takahashi N, Sugimoto M, Niimi K, Banno H, Komori K. Three cases of dorsal metatarsal artery bypass in patients with Buerger disease. <i>J Vasc Surg Cases Innov Tech<\/i> 2018; 4: 185\u2013188.","DOI":"10.1016\/j.jvscit.2018.03.011"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85. Ye K, Shi H, Qin J, Yin M, Liu X, Li W, et al. Outcomes of endovascular recanalization versus autogenous venous bypass for thromboangiitis obliterans patients with critical limb ischemia due to tibioperoneal arterial occlusion. <i>J Vasc Surg<\/i> 2017; 66: 1133\u20131142.e1.","DOI":"10.1016\/j.jvs.2017.03.425"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86. Lee CY, Choi K, Kwon H, Ko GY, Han Y, Kwon TW, et al. Outcomes of endovascular treatment versus bypass surgery for critical limb ischemia in patients with thromboangiitis obliterans. <i>PLoS One<\/i> 2018; 13: e0205305.","DOI":"10.1371\/journal.pone.0205305"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. Modaghegh MS, Hafezi S. Endovascular treatment of thromboangiitis obliterans (Buerger\u2019s disease). <i>Vasc Endovascular Surg<\/i> 2018; 52: 124\u2013130.","DOI":"10.1177\/1538574417744085"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88. Kawarada O, Kume T, Ayabe S, Nakaya T, Nakai M, Nishimura K, et al. Endovascular therapy outcomes and intravascular ultrasound findings in thromboangiitis obliterans (Buerger\u2019s disease). <i>J Endovasc Ther<\/i> 2017; 24: 504\u2013515.","DOI":"10.1177\/1526602817710917"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89. Firat A, Igus B. Endovascular recanalization of thromboangiitis obliterans (Buerger\u2019s disease) in twenty-eight consecutive patients and combined antegrade-retrograde intervention in eight patients. <i>Cardiovasc Intervent Radiol<\/i> 2019; 42: 820\u2013828.","DOI":"10.1007\/s00270-019-02193-x"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90. Soliman M, Mowafy K, Elsaadany NA, Soliman R, Elmetwally A. Thromboangiitis obliterans: Aggressive angioplasty provides a potential solution (randomized pilot study). <i>SAGE Open Med<\/i> 2020; 8: 205031212092763.","DOI":"10.1177\/2050312120927636"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91. Galyfos G, Liakopoulos D, Chamzin A, Sigala F, Filis K. A systematic review and meta-analysis of early and late outcomes after endovascular angioplasty among patients with thromboangiitis obliterans and chronic limb ischemia. <i>J Vasc Surg<\/i> 2023; 77: 1534\u20131541.e2.","DOI":"10.1016\/j.jvs.2022.09.017"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92. Lee AD, Agarwal S, Sadhu D. A 7-year experience with thoracoscopic sympathectomy for critical upper limb ischemia. <i>World J Surg<\/i> 2006; 30: 1644\u20131647.","DOI":"10.1007\/s00268-005-0559-y"},{"key":"93","unstructured":"93. Nakata Y, Suzuki S, Kawai S, Hirai M, Shinjo K. Effects of lumbar sympathectomy on thromboangiitis obliterans. <i>J Cardiovasc Surg<\/i> 1975; 16: 415\u2013425."},{"key":"94","unstructured":"94. Shionoya S, Ban I, Nakata Y, Matsubara J, Hirai M, Kawai S. Surgical treatment of Buerger\u2019s disease. <i>J Cardiovasc Surg<\/i> 1980; 21: 77\u201384."}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/90\/7\/90_CJ-25-0969\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T03:23:34Z","timestamp":1782530614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/90\/7\/90_CJ-25-0969\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":94,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-25-0969","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"article-number":"CJ-25-0969"}}